Some years are bigger than others, and by just about any measure, 2015 was a banner year for the lung cancer community. We saw new drug approvals for a wide range of lung cancer patients, including immunotherapy for patients with both squamous and non-squamous advanced NSCLC, as well as very recent approvals as holiday presents for patients with an EGFR mutation or ALK rearrangement. We saw many important trials in lung cancer become high priorities, a growing use of next generation sequencing to identify new targets, and new data and greater acceptance… Read More